DekaBank Deutsche Girozentrale Sells 2,617 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

DekaBank Deutsche Girozentrale reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 211,207 shares of the biopharmaceutical company’s stock after selling 2,617 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Regeneron Pharmaceuticals were worth $218,659,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of REGN. Stephens Consulting LLC bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $26,000. Sachetta LLC boosted its stake in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the last quarter. Crewe Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth $28,000. Lynx Investment Advisory purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at $33,000. Finally, Family Firm Inc. purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth about $33,000. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on REGN shares. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday. Leerink Partners restated a “market perform” rating and set a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Barclays dropped their target price on shares of Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating for the company in a report on Wednesday. Evercore ISI decreased their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Guggenheim upped their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $1,101.00.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $933.02 on Friday. The stock has a 50 day moving average price of $1,088.44 and a 200-day moving average price of $1,040.53. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20. The stock has a market cap of $102.86 billion, a price-to-earnings ratio of 24.71, a price-to-earnings-growth ratio of 3.29 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $8.79 earnings per share. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.66 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.